Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. - Wikidata - wikimedia - TriplyDB

Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial.

Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial.

http://www.wikidata.org/entity/Q38829062

about

Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy Immunotherapy for Gastroesophageal Cancer Gastric cancer: current and evolving treatment landscape Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment A unified model of the hierarchical and stochastic theories of gastric cancer.Role of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progress Gastric Cancer in the Era of Precision Medicine.Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal.Emerging therapies for breast cancer Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients.Molecular classifications of gastric cancers: Novel insights and possible future applications.Initiation and Maintenance of Gastric Cancer: A Focus on CD44 Variant Isoforms and Cancer Stem Cells.Inhibition of CXCL12/CXCR4 axis as a potential targeted therapy of advanced gastric carcinoma The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy.Biologic therapy in esophageal and gastric malignancies: current therapies and future directions Distal gastrectomy versus total gastrectomy for distal gastric cancer.Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability.Cancer immunotherapies targeting the PD-1 signaling pathway.Chemotherapy for advanced gastric cancer.PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy.PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence Cancer Immunotherapies: Are They as Effective in the Elderly?Folic acid-functionalized polyethylenimine superparamagnetic iron oxide nanoparticles as theranostic agents for magnetic resonance imaging and PD-L1 siRNA delivery for gastric cancer.A global burden of gastric cancer: the major impact of China.Immunotherapy for gastric cancers: emerging role and future perspectives.Gastric cancer management: Kinases as a target therapy.Second-line chemotherapy for patients with advanced gastric cancer.New agents on the horizon in gastric cancer.Genomic pathobiology of gastric carcinoma.Global chemotherapy development for gastric cancer.Chemotherapy for advanced gastric cancer: future perspective in Japan.An update in the nonendoscopic treatment of gastric cancer.Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.Challenges in molecular targeted therapy for gastric cancer: considerations for efficacy and safety.Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity.Advanced gastric adenocarcinoma: optimizing therapy options.Predictive biomarkers along gastric cancer pathogenetic pathways.Novel Targeted Therapies for Esophagogastric Cancer.The genetics of gastroesophageal adenocarcinoma and the use of circulating cell free DNA for disease detection and monitoring.Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.

P2860

Q28066199-5C7819CC-109A-4BE4-BD89-8033D1BF4B2D Q28069873-D339DE08-37FB-4F2F-A416-62B4CD0D8565 Q28073757-33EADC31-7D08-4D8D-B8AD-3C26FEC0A8FE Q28076294-FFE46562-FFA4-44C5-A19A-02A66BDC47BC Q33577624-83F00B24-FA33-4FF5-8532-1B7691BFA609 Q33593871-36ECB86C-39D1-4683-9381-B3A02A6C130B Q33600457-68462228-B3D8-4F46-8483-9FED4A04053D Q33608156-D5DA2111-B9CE-44DD-B70A-C1BF1C862852 Q33617949-E8F67407-29C8-40B1-9214-DC8D1D046BC6 Q33688662-5BC88BC5-5EBC-4BAA-8480-71052D5F9656 Q33696201-B33AD09B-76D0-4C77-B218-0D9282E6E59E Q33711746-9CAF1ED7-6ABC-4239-8DF9-04E489315B44 Q33775283-587565A0-C946-49A7-9396-80915C9F41D8 Q33888982-88C89CF7-04C3-4847-BEB3-9730E021CDFF Q33895597-2B5F4FEF-4008-4513-B8D2-1C15A2DB0E4C Q37626654-003EF37C-84A4-4C0B-9464-A14BDA6EE1C8 Q37706604-7CF792F4-A056-42E9-9AA7-A3B3AFC4CDDE Q37737940-C27EEE89-E9F8-46B2-9A0C-56FA1265BBB2 Q38604012-9571B9AD-5C4A-40AB-9D16-13B06383D744 Q38642853-C81608F5-E2BB-430B-B04D-6CC433FB524D Q38649562-C5AE3304-C7B0-4951-8EEA-1B0C27A82A1A Q38679662-0D3636BA-80B8-46D4-9289-B62C540BAEDA Q38695286-22E74C38-F450-459D-AB4D-4E1A4236094B Q38738402-39561D0D-1C99-4229-B734-944B6A25977E Q38738652-F3434818-DF9F-4B62-B998-D29E2E44A714 Q38749038-1E381348-CEEE-48CC-90FE-71865500B761 Q38750633-BE52D2E7-BBDF-44B8-8C52-48C2C2FF0977 Q38759129-908FB967-E42D-4579-9F0B-5DEB9D08B51F Q38779428-803C2C80-1ECF-41E9-9179-4A49E72A1DE7 Q38813532-F3920A4C-5E3B-446B-8FBA-0DFB3845BD63 Q38815071-0E74E026-6710-4746-AFA1-02366DD1730A Q38956298-6C9117BC-70CE-4F49-A253-10FC65314500 Q39013253-8ECA1D07-860B-44B0-BF14-701C4DE51E11 Q39038994-B765E4B2-BDAB-43F6-B592-6B9AABA8CB75 Q39069273-E85C5F9D-E6B5-4210-BDF6-6C2D5AAB9B72 Q39091817-D818BE48-6509-4EAD-A922-7870AE650C46 Q39170872-C3C34288-85D9-4888-B61C-8D0695A015B1 Q39171565-60671C04-8BF3-4BF8-900D-8F22F1E651AB Q39183864-1B8CFC4E-2DEE-474D-801D-DCE10B90E6E6 Q39193035-12836109-80B1-4AE0-BEA6-A86DB2B967E3

P2860

Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial.

http://www.wikidata.org/entity/Q38829062

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Pembrolizumab for patients wit ...... e, open-label, phase 1b trial.

@en

type

label

Pembrolizumab for patients wit ...... e, open-label, phase 1b trial.

@en

prefLabel

Pembrolizumab for patients wit ...... e, open-label, phase 1b trial.

@en

P1433

Q38829062-C045185D-3C99-404E-AAF8-E582C9CA2AB5

P1476

Q38829062-5D7168D8-6053-41C6-864E-9F7EB0466659

P2093

Q38829062-1048117C-A7F5-4BCD-94B5-07FFEDF21A97

Q38829062-114764CE-8FD8-4034-B5AA-3F28EACB3A83

Q38829062-13753CD1-EE12-4C93-8E00-DD01D0547F58

Q38829062-40FF8DF2-A523-4B34-BFC5-642581EEF33E

Q38829062-44C65265-E701-4AEB-9608-0DBA6751A1C3

Q38829062-56E1541F-DC77-47C9-BC2C-AB31F0435CD7

Q38829062-58976B9A-6683-4EE6-9774-C7D57D0382AD

Q38829062-67EC0C1A-3150-4838-867B-D0BC886292A7

Q38829062-6D8158F0-D850-4D4A-851D-B7066DE35C1E

Q38829062-78BF3788-DA4F-4AF9-BEEC-4E230CF11FBF

P304

Q38829062-EBC8D5C1-942D-4572-B18A-801DEFC609C1

P31

Q38829062-7E934D2B-DDE4-41CD-9BF2-10DBD8DDADFE

P356

Q38829062-6CEDD102-3F55-4828-B513-D6B78985C817

P433

Q38829062-C93A45DB-15AC-4C62-A938-040260B39DB8

P478

Q38829062-81409050-FDD5-4545-8FA0-594B10135148

P50

Q38829062-0E35CEA7-1A1C-4A12-9214-3E5D85E84B1A

P577

Q38829062-1A42A901-20D2-4DE6-A9EB-83F1345D6DA6

P698

Q38829062-43934BE0-CE3E-4B6D-9AE6-D5EC0A9084FC

P921

Q38829062-025B6B0F-4C86-4FE7-B753-4A8242CF6FD0

P356

S1470-2045(16)00175-3

P1433

The Lancet Oncology

P1476

Pembrolizumab for patients wit ...... e, open-label, phase 1b trial.

@en

P2093

Autumn J McRee

http://www.w3.org/2001/XMLSchema#string

Barbara Burtness

http://www.w3.org/2001/XMLSchema#string

Chia-Chi Lin

http://www.w3.org/2001/XMLSchema#string

Daniel Catenacci

http://www.w3.org/2001/XMLSchema#string

Dung T Le

http://www.w3.org/2001/XMLSchema#string

Jared Lunceford

http://www.w3.org/2001/XMLSchema#string

Jonathan Juco

http://www.w3.org/2001/XMLSchema#string

Joseph Paul Eder

http://www.w3.org/2001/XMLSchema#string

Kei Muro

http://www.w3.org/2001/XMLSchema#string

Kenneth Emancipator

http://www.w3.org/2001/XMLSchema#string

P304

717-726

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1470-2045(16)00175-3

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

Hyun Cheol Chung

P577

2016-05-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27157491

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial